Schrödinger Q2 FY24 Investor Presentation Update

Schrödinger presents Q2 FY24 business update highlighting its science-based software and consulting solutions for pharmaceutical R&D. The company focuses on accelerating drug development timelines and reducing costs through innovative computational tools and the integration of recently acquired Immunetrics business.